Westfield Capital Management’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$163M Buy
1,287,629
+1,260,939
+4,724% +$166M 0.53% 49
2026
Q1
$3.72M Sell
26,690
-14,825
-36% -$2.08M 0.02% 212
2025
Q4
$5.1M Buy
+41,515
New +$5.05M 0.02% 211
2024
Q1
Sell
-100,981
Closed -$8.18M 250
2023
Q4
$8.18M Buy
100,981
+2,093
+2% +$163K 0.05% 193
2023
Q3
$7.41M Buy
98,888
+6,137
+7% +$472K 0.05% 183
2023
Q2
$7.15M Buy
92,751
+5,991
+7% +$478K 0.05% 184
2023
Q1
$7.2M Buy
86,760
+3,165
+4% +$262K 0.05% 187
2022
Q4
$7.18M Buy
83,595
+4,666
+6% +$370K 0.06% 183
2022
Q3
$4.87M Sell
78,929
-2,326
-3% -$147K 0.04% 195
2022
Q2
$5.02M Buy
+81,255
New +$5.03M 0.04% 199
2017
Q2
Sell
-45,465
Closed -$3.09M 263
2017
Q1
$3.09M Sell
45,465
-1,356,514
-97% -$95.4M 0.03% 235
2016
Q4
$100M Sell
1,401,979
-130,839
-9% -$9.73M 0.88% 27
2016
Q3
$121M Buy
+1,532,818
New +$125M 0.98% 24

Other funds holding GILD

Westfield Capital Management's GILD Position: Q2 2026 in Review

Westfield Capital Management increased its Gilead Sciences (GILD) stake by 4,724% in Q2 2026, buying an estimated $166M and bringing the position to 1,287,629 shares worth $163M. The position accounts for 0.53% of the portfolio, ranked #49.

Westfield Capital Management first reported a position in GILD in Q3 2016 and has held it in 13 quarters since. 2,278 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Westfield Capital Management held 1,287,629 shares of Gilead Sciences worth $163M as of Q2 2026.
  • Westfield Capital Management bought 1,260,939 Gilead Sciences shares in Q2 2026, an estimated $166M.
  • Gilead Sciences made up 0.53% of Westfield Capital Management's portfolio in Q2 2026, its #49 holding.
  • Westfield Capital Management first reported a position in Gilead Sciences in Q3 2016 and has held it in 13 quarters since.
  • 2,278 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Westfield Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.